Jae Lyn Burke, PA-C Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 66 Park Street, Elizabethtown, NY 12932 Phone: 518-873-6896 |
Mrs. Mary Buehler-brandt, RPA Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 66 Park Street, Elizabethtown, NY 12932 Phone: 518-873-6377 Fax: 518-873-6578 |
Mr. James Whalen L'episcopo, P.A. Physician Assistant Medicare: Medicare Enrolled Practice Location: 75 Park St, Elizabethtown, NY 12932 Phone: 518-873-6377 Fax: 518-873-2091 |
James F Jackson, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 75 Park St, Elizabethtown, NY 12932 Phone: 518-873-6377 Fax: 518-873-2315 |
Mr. Matthew Jude Hinge, RPA-C. MSPA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 75 Park St., Elizabethtown, NY 12932 Phone: 518-873-6377 |
Mr. Robert Alan Andrews, RPA-C Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 75 Park St, Elizabethtown Community Hospital, Elizabethtown, NY 12932 Phone: 518-873-6377 |
News Archive
Ninety-nine percent of cervical cancers are caused by human papillomavirus (HPV). More than 200 HPVs, some of which are associated with varying degrees of cancer risk, complicate diagnosis and treatment.
While prescription medications work successfully to cure an ailment in some people, in others the same dose of the same drug can cause an adverse reaction or no response at all.
Planned Parenthood of Kansas and Mid-Missouri last week filed a second lawsuit in Jackson County, Mo., asking the court to exclude clinics that offer only medical abortions from a state law (SB 370) designating facilities providing some abortions as "ambulatory surgical centers" to exclude clinics that offer only medical abortions, the AP/Hays Daily News reports.
PENTAX Medical launches a world first for endoscopy, the OPTIVISTA EPK-i7010 Video Processor, featuring both digital and optical enhancements, in the European, Middle Eastern & African (EMEA) markets.
Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of AvastinĀ® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.
› Verified 4 days ago